BOSTON, SAN FRANCISCO, and REDMOND, Wash., April 1, 2021 – Pear Therapeutics, Inc. and Prescryptive Health today announced that Prescryptive, the first health intelligence platform, will offer and administer benefit coverage for reSET® and reSET-O®, the first two prescription digital therapeutics (PDTs) to receive authorization from the U.S. Food and Drug Administration (FDA) to treat disease. reSET and reSET-O have been added to Prescryptive’s formularies and are being administered as standard pharmacy benefits for its members.
“Prescryptive has launched the world’s first health intelligence platform powered by blockchain that delivers patients the necessary prescription information they need in real-time to their mobile device while they are engaged with their healthcare provider,” said Chris Blackley, CEO of Prescryptive Health. “Teaming with Pear to make reSET and reSET-O available to our members is a natural extension of our aim to deliver empowering benefit plan solutions that inspire better health.”
“With an aligned mission to engage patients and redefine the delivery of care, we are pleased to team with Prescryptive to provide people in recovery with covered access to innovative FDA-authorized treatments through their mobile devices when and where they need it most,” said Corey McCann, M.D., Ph.D., President and CEO of Pear Therapeutics. “With this coverage decision, Pear continues to expand access to PDTs by adding reSET and reSET-O to a standard formulary.”
As Prescryptive Health and Pear both have a commitment to delivering digital solutions at the point-of-care, in a mobile-enabled environment that’s patient-centric, the collaboration drives transparency and control for members when they need care most.
Prescryptive will include reSET and reSET-O on its platform, making a seamless experience for members who will benefit from PDTs. Both reSET and reSET-O have been tested in real-world use and randomized controlled trials, with results published in peer-reviewed medical journals. Both products, which are adjunctive to outpatient counselling, provide patients with algorithm-driven cognitive behavioral therapy, fluency training, and contingency management, while clinicians receive access to clinical dashboards to inform in-office and tele visits. reSET is used as a monotherapy for patients 18 years of age or older with substance use disorder and reSET-O is used in combination with transmucosal buprenorphine for patients 18 years of age or older with opioid use disorder.
PDTs are a new therapeutic class that uses software to directly treat disease. Like traditional medicines, PDTs are developed in a GMP-compliant environment, tested in randomized controlled trials demonstrating safety and effectiveness, evaluated and authorized by regulators like FDA, and used under the supervision of a prescribing clinician1,2. Unlike traditional medicines, PDTs are designed to collect real world data for use by prescribing clinicians and for population health management by payors and health systems. Pear recently released publications showing the potential for improved health outcomes and decreased treatment costs for patients using reSET-O3-7.
About Prescryptive Health
Prescryptive is putting an end to the U.S. drug debacle with the world’s first health intelligence platform, eliminating middlemen from the drug market to let consumers take charge of their medication costs. By delivering a simple, mobile experience that integrates in real-time with their benefit plan and provider, Prescryptive Health is transforming the prescription drug market and the pharmacy experience by empowering consumers, cutting costs, and inspiring better health. To learn more about how we’re rewriting the script, visit www.prescryptive.com.
About Pear Therapeutics
Pear Therapeutics is the leader in prescription digital therapeutics or PDTs. Pear aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s lead product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.
